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1. Introduction 
The underuse of vitamin K antagonists (VKAs) among elderly patients with atrial fibrillation 
(AF) has been confirmed in different settings [1], [2], [3], [4], [5] and [6]. Indeed, the 
CHA2DS2–VASc [6] and [7], that assigns 2 points (and not 1 as CHADS2[8]) to age ≥ 75 
years, and 1 point to age ≥ 65 years would qualify all patients older than 75 years as 
candidates for long term anticoagulation, and all patients older than 65 years for aspirin 
treatment, even in the absence of other risk factors [9], [10] and [11]. 
Since the fear of treatment-related bleeding is the most likely reason for the under-
prescription of anticoagulants, tools for the prediction of the risk of bleeding in patients with 
AF on VKAs have been proposed [12], [13], [14] and [15]. All the available scores for 
bleeding risk include older age among risk factors. The different therapeutic guidelines 
frame their recommendations on the degree of cardio-embolic risk based upon CHADS2 
or CHA2DS2–VASc, but fail to express uniform agreement on the use and usefulness of 
bleeding scores, although suggesting of considering the patient bleeding risk to decide on 
the long-term antithrombotic therapy [9], [10] and [11]. Moreover, it is still controversial 
whether and to which extent the decisions on cardio-embolic prophylaxis in the most 
common population of patients with AF (the oldest old with multimorbidity) currently rely 
upon a joint assessment of both cardio-embolic and bleeding risks. 
With this background, we analyze retrospectively patients older than 65 years with atrial 
fibrillation or flutter (AFF) enrolled in REPOSI [16] during the first (2008) and the second 
(2010) collection waves of this registry, with the aims to describe: i) the stratification of 
patients according to the different scores for cardio-embolic and bleeding risks; ii) the 
within-patient relationship between cardio-embolic and bleeding risks as defined by these 
scores; iii) whether or not the prescription of antithrombotic therapy was related to the 
score-based assessment of cardio-embolic and bleeding risks. 
 
2. Materials and methods 
2.1. Study population 
Patients analyzed in this study were recruited in the frame of the ‘REgistro POliterapie 
SIMI’ (REPOSI) [16]. The REPOSI is a collaborative and independent Registry organized 
by the Italian Society of Internal Medicine (SIMI) and the Mario Negri Institute of 
Pharmacological Research in Milan with the purpose to create a network of internal 
medicine and geriatric wards in order to evaluate hospitalized patients older than 65 years 
affected by multiple diseases and prescribed with polypharmacy. Patients recruited for 
REPOSI in 2008 and 2010, and admitted to the participating Italian wards with a known 
diagnosis of AFF (International Classification of Diseases — Ninth Revision [ICD-9] codes 
427.31 or 427.32) were analyzed in this study. Patients newly diagnosed with AFF during 
the index hospitalization were not included. 
 
2.2. Cardio-embolic and bleeding risk stratification 
The patient population was retrospectively classified according to the cardio-embolic risk 
as predicted by CHADS2 and CHA2DS2–VASc scores [6] and [7], and according to the 
bleeding risk as predicted by HEMORR2HAGES and HAS-BLED scores [12] and [14]. The 
components of each score, the annual event rates associated with the risk categories as 
reported in the literature, as well as the corresponding absolute risk reduction or increase 
with VKAs are summarized in online Appendix A. The scores were retrospectively 
calculated for each patient using the data collected at admission on socio-demographic 
characteristics, clinical history and drug use before the hospitalization and the reason for 
hospitalization. A modified HEMORR2HAGES score not including genetic risk factors, and 
a modified HAS-BLED score, not including the labile INR factor were used, because the 
corresponding data were not available in REPOSI; both these modified versions of the 
scores have already been used and validated [12], [14] and [17]. The resulting risks were 
reported both as continuous scores and as categories (low, intermediate, high),  
using for the latter the originally proposed score-based stratifications [6], [12], [14], [17] 
and [18] (online Appendix A). Classification of patients' cardio-embolic risk was compared 
using both scores, and the classification of patients' bleeding risk using both scores. We 
then described the co-stratification of the study population using both a scheme for the 
cardio-embolic risk and one for the bleeding risk, testing different combinations. 
Correlation between scores, as a measure for trend, was tested by the Spearman test. 
Concordance/discordance between risk categories was expressed as percentage of 
patients classified into the same/different risk category. Although risk categories are 
categorical ordinal variables, linear regression analyses were used to show the average 
association between the risk categories as defined using the different scores. For this 
purpose the low, intermediate and high risk categories were coded as 0, 1 and 2, 
respectively. 
 
2.3. Antithrombotic therapy and risk scores 
The study population was characterized according to the antithrombotic therapy recorded 
at hospital admission, considering as long-term therapy VKAs and antiplatelet drugs 
(aspirin, clopidogrel, ticlopidine and aspirin plus dypyridamole). To evaluate retrospectively 
the association between the cardio-embolic/bleeding risk scores and the prescribed 
antithrombotic therapy, two sets of analyses were performed. 
a. 
Risk scores as predictors of VKA prescription. A classic logistic regression was used to 
evaluate this relationship, in simple and multivariable analyses (including both cardio-
embolic and bleeding score as predictors). CART (Classification and Regression Trees 
analysis) [19] was also used as a multivariable approach to further explore how the scores 
were hierarchically associated with VKA prescription. The program automatically selected 
for each score the best-splitting value for the therapeutic choice, i.e. that value above or 
below which VKAs were more likely to be prescribed or not. 
b. 
Risk scores as predictors of antithrombotic therapy type. With the aim of taking into 
account all the possible antithrombotic options for AFF, a 4-level nominal variable was also 
used as dependent variable, coded as 0 for no therapy, 1 for antiplatelet therapy, 2 for 
VKAs, and 3 for VKAs plus antiplatelet agents. The variable levels were chosen in order to 
simulate an ordinal variable where each further level corresponded to an increasing 
antithrombotic burden. The association between this variable and the scores was explored 
using an ordered logistic regression when the proportional odds assumption was met, i.e. 
when the effect of the score on each therapeutic step was constant (theomodel user's 
command for STATA was used to verify the assumption). If this assumption was not met, a 
multinomial logistic regression was used, where the no-therapy choice was taken as 
reference and the association of the score with any other therapeutic choice was 
compared to the reference. 
Then the analyses exploring the association between the risk scores and antithrombotic 
therapy were repeated adjusting for patient age, in order to look at the effect of the scores 
after holding the patient age constant; this is equivalent to remove the effect of age (a 
component of the scores) from the effect of the scores. 
In order to take into account the multi-center origin of the REPOSI data, we adopted robust 
variance estimates that were obtained in all regression models by means of the 
Huber/White/sandwich estimator which considers observations as independent across 
groups (the REPOSI centers in this case). 
STATA was used to perform all the analyses (version 12, Statacorp, College Station, Tx, 
US). 
 
3. Results 
3.1. Study population 
The 2008–2010 installments of REPOSI included 2712 patients, 1332 enrolled in 2008 and 
1380 in 2010. Five hundred and forty-three patients (20.0%) were admitted to hospital with 
a known diagnosis of AFF, 247 in 2008 (18.5%) and 296 in 2010 (21.4%). Patients with 
AFF at admission (Table 1) were significantly older than those without (median age = 81.1, 
range 65.4–100.6 years, versus median age = 78.6, range 65.0–101.4 years, p < 0.001); 
approximately 80% of patients were older than 75 years. Two hundred sixty-five were 
males (48.8%), with no difference in gender composition compared to patients without 
AFF. Twenty-eight patients with AFF at admission (5%) died during the hospitalization. 
Table 1 shows also the proportion of patients presenting a stroke or a bleeding event as 
reason for admission or during the hospital stay. 
 
3.2. Cardio-embolic and bleeding risk stratification 
Table 1 reports the mean and median score values at admission. Table 2 shows how the 
study population was stratified into cardio-embolic and bleeding risk categories based 
upon the different scores. A high correlation was found between the two cardio-embolic 
risk scores (Spearman correlation coefficient 0.86, p value < 0.001), but with a 
discordance of 25% between the two risk classifications. In detail, all patients classified at 
intermediate or high risk using CHADS2 were classified at high risk according to 
CHA2DS2–VASc; patients with a low cardio-embolic risk according to CHADS2 were 
reclassified by CHA2DS2–VASc as having an intermediate (9 of 16, 56%) or a high (7 of 
16, 43%) risk. There was a high correlation between the two bleeding risk scores 
(Spearman correlation coefficient 0.82, p value < 0.001), but with a discordance of 43% 
between the two risk classifications. In detail, nearly all (117 of 119, 98%) patients 
classified at high risk according to HEMORR2HAGES were classified at high risk also 
according to HAS-BLED; 57% (193/340) of patients classified at intermediate risk 
according to HEMORR2HAGES were also classified at intermediate risk according to 
HAS-BLED, whereas the remaining 43% patients (147/340) were classified at high HAS-
BLED risk. Patients with a low bleeding risk according to HEMORR2HAGES were 
classified at intermediate (83 among 84, 99%) or, in one case only, at high HAS-BLED 
risk. Fig. 1 (plots a and b) in the online Appendix B exemplifies the average relationship 
between risk categories defined by each couple of scores. 
Table 3 shows how the study population was co-classified according to both the cardio-
embolic and bleeding risks using two different score combinations. The Spearman 
correlation between CHADS2 and HEMORR2HAGES scores and between CHA2DS2–
VASc and HAS-BLED scores was, respectively, 0.424 and 0.316. Most of the patients 
were at high cardio-embolic/high-intermediate bleeding risk (70.5% when CHADS2 plus 
HEMORR2HAGES were used, 98.3% when CHA2DS2–VASc plus HAS-BLED were 
used). Plots c, d, e and f in Fig. 1 (online Appendix A) show the average relationship 
between cardio-embolic and bleeding risk categories using the 4 possible score 
combinations. 
According to the predicted risk associated with the scores reported in the original papers 
(see the online Appendix A for details): White cells: the predicted annualized cardio-
embolic risk tends to be larger than the predicted annualized bleeding risk (and the 
predicted absolute risk reduction of cardio-embolic events with warfarin tends to be larger 
than the predicted absolute risk increase of bleeding events with warfarin). Dark gray cells: 
the predicted annualized bleeding risk tends to be larger than the predicted annualized 
cardio-embolic risk (and the predicted absolute risk increase of bleeding events with 
warfarin tends to be larger than the predicted absolute risk reduction of cardio-embolic 
events with warfarin). Light gray cells: the predicted annualized bleeding risk tends to be 
equal or larger than the predicted annualized cardio-embolic risk (and the predicted 
absolute risk increase of bleeding events with warfarin tends to be equal or larger than the 
predicted absolute risk reduction of cardio-embolic events with warfarin). Predicted 
denotes as reported in score validation studies. 
 
3.3. Antithrombotic therapy and risk scores 
The antithrombotic therapy that REPOSI patients were receiving at admission is shown in 
Table 1. 
 
3.3.1. Risk scores as predictors of VKA prescription 
Table 4 reports the number and percentage of patients on VKAs in each cell co-defined by 
the cardio-embolic and bleeding risk. The highest rate of VKA prescription was found 
among patients at intermediate cardio-embolic and low bleeding risk when the 
CHADS2/HEMORR2HAGES co-classification was used, and among patients at high 
cardio-embolic and intermediate bleeding risk when the CHA2DS2–VASc/HAS-BLED 
combination was used (ignoring the 100% cell including only 1 patient). In simple logistic 
regressions, a higher bleeding score, using either HEMORR2HAGES or HAS-BLED, was 
associated with a lower probability to receive VKA (p < 0.001). Neither cardio-embolic risk 
score was significantly associated with VKAs prescription in unadjusted analysis. Only 
after adjusting for the bleeding risk score (either HEMORR2HAGES or HAS-BLED) was a 
higher cardio-embolic risk score (either CHADS2 or CHA2DS2–VASc) associated with a 
higher probability to receive VKAs (p < 0.001 for any combination). When all the 4 scores 
were included as covariates, the HEMORR2HAGES and CHADS2 scores remained 
significant predictors. The CART analysis confirmed these results, and pointed out that a 
low bleeding risk score seemed to affect positively the probability of VKA prescription, 
whereas cardio-embolic risk scores were associated with the probability of VKA 
prescription only among higher bleeding risk scores (Fig. 2 in the online Appendix A). 
According to the predicted risk associated with the scores reported in the original papers 
(see the online Appendix A for details): White cells: the predicted annualized cardio-
embolic risk tends to be larger than the predicted annualized bleeding risk (and the 
predicted absolute risk reduction of cardio-embolic events with warfarin tends to be larger 
than the predicted absolute risk increase of bleeding events with warfarin). Dark gray cells: 
the predicted annualized bleeding risk tends to be larger than the predicted annualized 
cardio-embolic risk (and the predicted absolute risk increase of bleeding events with 
warfarin tends to be larger than the predicted absolute risk reduction of cardio-embolic 
events with warfarin). Light gray cells: the predicted annualized bleeding risk tends to be 
equal or larger than the predicted annualized cardio-embolic risk (and the predicted 
absolute risk increase of bleeding events with warfarin tends to be equal or larger than the 
predicted absolute risk reduction of cardio-embolic events with warfarin). Predicted 
denotes as reported in score validation studies. 
 
3.3.2. Risk scores as predictors of the type of antithrombotic therapy 
When an ordered 4-level variable was used for antithrombotic therapy, the proportional 
odds assumption was met for both cardio-embolic risk scores, i.e. higher scores were 
associated to therapeutic choices with a higher antithrombotic potency, but in a quasi 
statistically significant way only for CHADS2 (p = 0.054). The proportional odds 
assumption was not met for the bleeding risk scores. In simple multinomial analysis, and 
also after adjusting for any cardio-embolic risk score, the HEMORR2HAGES score was 
associated with the therapeutic choice, but in different ways: a higher HEMORR2HAGES 
score was negatively associated with the prescription of VKA compared to no therapy, but 
it was positively associated with the prescription of antiplatelet agents compared to no 
therapy. A direct association between a higher score and antiplatelet prescription was also 
found for the HAS-BLED score in simple multinomial logistic regression, and after 
adjusting for any cardio-embolic risk score. Conversely HAS-BLED was not associated 
with the prescription of VKA. None of the reported findings changed when patients on 
LMWH or fondaparinux were excluded from the analyses. After adjusting for patient age, 
both the cardio-embolic risk scores became significantly associated with the antithrombotic 
therapy in all types of analysis even without adjusting for the bleeding risk scores. All the 
remaining results did not change. 
 
4. Discussion 
The REPOSI registry was designed in order to collect data on a representative sample of 
patients admitted to internal medicine wards, increasingly characterized in Italy and 
elsewhere in Europe by advanced age and multimorbidity. The first aim of these post-hoc 
analyses was to describe how the available scores for cardio-embolic and bleeding risks 
would classify patients with AFF in this complex population. We then evaluated whether or 
not risk assessment according to the scores was related the choice of antithrombotic 
therapy. 
The main novelty of this study was to look, albeit retrospectively, at the co-classification of 
this elderly population using a combination of scores for both cardio-embolic and bleeding 
risk, that might theoretically provide the physician with a higher potential for tailoring each 
individual treatment than using a strategy based only on the cardio-embolic. As expected, 
the REPOSI population was on average both at high cardio-embolic and bleeding risk (see 
Table 2a), even though the patients' cardio-embolic risk category tended to be higher than 
the bleeding risk category. In particular, the percentage of patients belonging to a cardio-
embolic risk category higher than the bleeding risk category was more than 60% when 
CHADS2 plus HEMORR2HAGES were jointly used, and approximately 50% when 
CHA2DS2–VASc plus HAS-BLED were used. This co-classification would apparently lead 
to recommend anticoagulation for approximately 50% of REPOSI patients. However, the 
same definitions for risk category (i.e. low, intermediate or high) for different scores do not 
correspond to the same annual risk of stroke or bleeding (and so to the same absolute 
effect of the treatment), as reported in the online Appendix A. In addition, a more 
appropriate way of using the score-based predictions of risk to individualize treatment 
recommendations should take into account also the different weight that a patient might 
assign to such clinical events, as stroke and bleeding [20], [21] and [22]. 
Our data confirm the well-known reclassification effect of CHA2DS2–VASc [6], [7] and [19], 
which moved almost all patients at low and intermediate CHADS2 score to the high risk 
category. As expected by definition for a ≥ 65 year population, none of the REPOSI 
patients was classified as having a low CHA2DS2–VASc risk [7] and [19], with the 
implication that according to this score all REPOSI patients with AFF would be treated with 
anticoagulants. 
The cardio-embolic risk stratification of REPOSI patients resembled that recently 
described in an elderly cohort from the UK General Practice Research Database (GPRD) 
[5]. However, the REPOSI population had a higher representation of patients at 
intermediate-high CHADS2 score, presumably because of a higher mean age and different 
selection criteria (patients at the time of hospital admission, with a likely higher rate of 
morbidity than those referred to general practitioners). 
There was also a high representation of the high risk category for bleeding among 
REPOSI patients, higher than in the UK cohort [5]. As for the cardio-embolic scores, a 
reclassification effect with HAS-BLED was observed compared to HEMORR2HAGES. 
Indeed, none of the REPOSI patients was at low HAS-BLED risk (because of age, none 
had a 0 score), and in 40% of them HAS-BLED classified patients into a higher risk 
category than HEMORR2HAGES. This effect was attenuated provided that a HAS-BLED 
score of 1 was included in the low risk category together with score 0 (as done in other 
studies [5] and [18]), yet only 11% of patients had a HAS-BLED score of 1. In fact, HAS-
BLED was developed in order to provide a therapeutic guideline easier to memorize and 
includes more practicable risk factors than HEMORR2HAGES [14]. 
We observed a low overall rate of prescription of VKAs, confirming a previous analysis 
based on REPOSI[16]. More interesting, the distribution of the percentages of patients 
treated with VKAs across the cells defined by the scores (Table 3) and the results of the 
logistic analyses showed that the patient's bleeding risk, but not the cardio-embolic risk 
alone, predicted the therapeutic choice. These findings on the relationship between the 
bleeding score and VKA prescription are consistent with those of the UK cohort [5]. In the 
literature, evidence on the relationship between cardio-embolic scores and VKA 
prescription in real settings is not uniform [5], [23] and [24]. In the present study, the 
cardio-embolic risk was a predictor of VKA prescription, only after adjusting for the 
bleeding score or patient age. In addition, the association found between a higher bleeding 
score and antiplatelet therapy clearly confirms the tendency to prescribe aspirin in clinical 
practice when evidence or perception of a higher risk of bleeding prevents VKA 
prescription. Irrespective of the cardio-embolic risk, this situation materializes especially in 
the elderly, even though this behavior is not justified by a safer profile of aspirin compared 
to VKAs [25] and [26], and either by a clear efficacy of aspirin [27]. 
This study has several limitations. First, a certain degree of underreporting is expected 
because of the post-hoc nature of our research question. Thus, it is possible that the 
actual risk scores were underestimated. Second, this was only an indirect and theoretical 
investigation of the association between patients' risks and physician's decisions, because 
it is not known whether or not REPOSI physicians applied these scores to take decisions. 
Another limitation is the assumption that the risk scores proposed in the literature for 
patients with AFF have a good predictive ability in a REPOSI-like elderly population. A 
further fundamental step should be the evaluation of the impact on patient outcomes of a 
decision strategy based on combined cardio-embolic and bleeding risk assessment 
compared to a strategy of cardio-embolic risk assessment alone. 
 
Learning points 
o Scores for cardio-embolic and bleeding risk in patients with atrial fibrillation are 
described in the literature to aid at tailoring the long term antithrombotic therapy; all 
of them include age as risk factor. 
o We observed how the available scores (CHADS2 and CHA2DS2–VASc, for cardio-
embolic risk, and HEMORR2HAGES and HAS-BLED, for bleeding risk) co-
classified complex elderly patients with multimorbidity admitted to Italian internal 
medicine and geriatric wards, and we confirmed that they configured a population 
both at high cardio-embolic and at high bleeding risk. 
 
o 50–60% of patients (depending on the score couples used) were classified in a 
cardio-embolic risk category higher than the bleeding risk category. 
 
o In those patients, the prescription and the type of antithrombotic therapy appeared 
to be primarily influenced by the bleeding risk; both the cardio-embolic scores were 
associated with the therapeutic choice only after adjusting for the patient bleeding 
score or age. 
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Table 1. 
Demographic and clinical characteristics of the study populationa. 
Characteristic  
Male, n (%) 265 (48.8) 
Mean age ± SD (median, range) 81.0 ± 7.3 (81.1, 65.4–
100.6) 
Median number of drugs per patient (range) 6 (1–15) 
Mean CHADS2 ± SD (median, range) 2.2 ± 1.1 (2, 0–6) 
Mean CHA2DS2–VASc ± SD (median, range) 3.8 ± 1.2 (4, 1–9) 
Mean HEMORR2HAGES ± SD (median, range) 2.6 ± 1.2 (3, 0–7) 
Mean HAS-BLED ± SD (median, range) 2.6 ± 1.1 (2, 1–6) 
Oral antithrombotic therapy at admission, n (%)b  
Characteristic  
 Vitamin K antagonist 210 (38.7) 
 Antiplatelet agent 174 (32.0) 
 VKA + antiplatelet 16 (3.0) 
 None 143 (26.3) 
Stroke as reason for admission, n (%) 22 (4.0) 
Stroke as adverse event during the hospital stay, n 
(%) 
2 (0.4) 
Bleeding as reason for admission, n (%) 16 (2.9)c 
Bleeding as adverse event during the hospital stay, n 
(%) 
8 (1.5)c 
 
a The risk scores were calculated counting the risk factors at admission.  
b 15% of patients not receiving VKAs at admission were on low molecular weight 
heparin (LMWH) or fondaparinux at therapeutic or prophylactic doses.  
c Two patients presented a bleeding event both as reason for admission and during 
the hospital stay. 
 
Table 2. 
Risk stratification according to cardio-embolic and bleeding scores. 
a. Cardio-embolic risk scores 
 
Cardio-embolic risk category CHADS2 
 
CHA2DS2–VASc 
 
Score Number of patients % Score Number of patients % 
Low 0 16 3.0 0 0 0 
Intermediate 1 118 21.7 1 9 1.7 
High ≥ 2 409 75.3 ≥ 2 534 98.3 
 
b. Bleeding risk scores 
Bleeding risk category HEMORR2HAGES HAS-BLED 
Score Number of patients % Score Number of patients % 
Low 0–1 84 15.5 0 0 0 
Intermediate 2–3 340 62.6 1–2A 278 51.2 
High ≥ 4 119 21.9 ≥ 3 265 48.8 
A 60 patients (11.0%) had a HAS-BLED score 1. 
 
Table 3. 
Patient distribution according to cardio-embolic and bleeding risk categories: number of 
patients (% of the whole population). 
 
 
 
 
 
 
Table 4. 
Frequency of VKA prescription according to cardio-embolic and bleeding risk categories: 
number of patients (% of the total number of patients in each cell). 
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Box 1. Stroke Risk Stratification with CHADS2 and CHA2DS2-VASc score 
CHADS2 items Points 
Congestive heart failure/left ventricular dysfunction 1 
Hypertension 1 
Aged ≥ 75 years 1 
Diabetes mellitus 1 
Stroke/TIA/systemic embolism 2 
  
Maximum score 6  
CHA2DS2-VASc items Points 
Congestive heart failure/left ventricular dysfunction 1 
Hypertension 1 
Aged ≥ 75 years 2 
Diabetes mellitus 1 
Stroke/TIA/systemic embolism 2 
Vascular disease (prior MI, PAD or aortic plaque) 1 
Sex gender 1 
Age 65-74 years 1 
  
Maximum score 9  
Legend: TIA, Transient Ischemic Attack. MI, Myocardial Infarction. PAD, Peripheral Artery Disease 
CHADS2 risk categories 
Low risk: score 0 
Intermediate risk: score 1 
High risk: score ≥ 2 
CHA2DS2-VASc risk categories 
Low risk: score 0 
Intermediate risk: score 1 
High risk: score ≥ 2 
Box 2. Bleeding risk stratification with HEMORR2HAGES and HAS-BLED score 
HEMORR2HAGES items Points 
Hepatic or renal disease 1 
Ethanol abuse 1 
Malignancy 1 
Aged ≥ 75 years 1 
Reduced platelet count or function* 1 
Rebleeding risk 2 
Hypertension 1 
Anemia 1 
Genetic factors 1 
Excessive fall risk or neuropsychiatric disease 1 
Stroke 1 
  
Maximum score 12  
HAS-BLED items Points 
Hypertension 1 
Abnormal renal or liver function 1 each 
Stroke 1 
Bleeding 1 
Labile INR 1 
Elderly (aged ≥ 65 years) 1 
Drugs
∫
 or alcohol 1 each 
  
Maximum score 9  
*Aspirin use. 
∫
Antiplatelet agents or nonsteroidal anti-inflammatory drugs. 
HEMORR2HAGES risk categories 
Low risk: score 0-1 
Intermediate risk: score 2-3 
High risk: score ≥ 4 
HAS-BLED risk categories 
Low risk: score 0 
Intermediate risk: score 1-2 
High risk: score ≥ 3 
 
 
Box 3. Score-based risk categories and reported annualized event rate as events/100 person-years 
(confidence interval in the original study)* 
 Low Risk Intermediate Risk High Risk 
CHADS2 [8] 1.9 (1.2-3.0) 2.8 (2.0-3.8) 4.0-18.2 (3.1 – 27.4) 
CHA2DS2–VASc [6] 
CHA2DS2–VASc [22]
 
0 
0.6 
0.7 
1.3 
1.9-14.2 
2.8-15.9 
HEMORR2HAGES [12] 
HEMORR2HAGES [18] 
1.9-2.5 (0.6-4.3) 
3.1 (2.8-3.3) 
5.3-8.4 (3.4-13.6) 
6.3 (5.9-6.7] 
10.4-12.3 (5.1-23.1) 
12.2 (11.1-13.3) 
HAS-BLED [22] 
HAS-BLED [18] 
2.8 
2.7 (2.4-2.9)
∫
 
7.1-12.4 
5.5 (5.2-6.0) 
14.9-35.4 
8.1 (7.6-8.6) 
*For cardio-embolic events among patients off VKA; for bleeding events, among patients on VKA 
#
Back-calculated from the rates in patients off VKA, considering a RR of 2.3 for bleeding with warfarin 
∫
HAS-BLED scores 0 and 1 were included in low risk category 
 
 
Box 4. Score-based risk categories and associated absolute risk reduction of cardio-embolic events (per 
100 person-years) and absolute risk increase of bleeding events (per 100 person-years) with warfarin, 
using a relative risk for cardio-embolic events of 0.36 and a relative risk for bleeding event of 2.30 with 
warfarin vs placebo 
 Low Risk Intermediate Risk High Risk 
CHADS2 [8] 1.2  1.8  2.6-11.6  
CHA2DS2–VASc [6] 
CHA2DS2–VASc [22]
 
0 
0.4 
0.4 
0.8 
1.2-9.1 
1.8-10.2 
HEMORR2HAGES [12] 
HEMORR2HAGEs [18] 
1.1-1.4 
1.7  
3.0-4.7  
3.6  
5.9-6.9  
6.9  
HAS-BLED [22] 
HAS-BLED [18] 
1.6 
1.5
∫
 
4.0-7.0 
3.1  
8.4-20.0 
4.6  
*For cardio-embolic events among patients off VKA; for bleeding events, among patients on VKA 
#
Back-calculated from the rates in patients off VKA, considering a RR of 2.3 for bleeding with warfarin 
∫
HAS-BLED scores 0 and 1 were included in low risk category
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Figure legend. 
Figure 1. Relationship between risk categories according to cardio-embolic and bleeding risk scores, 
based on standard linear regressions 
The six plots show the relationship between risk categories as defined by couples of scores. Assuming that 
the classification into risk categories can approximate an ordinal variable, a value of 0, 1 and 2 was assigned 
to, respectively, a low, intermediate and high risk category. The x- and y-axis labels reflect this coding: 0 = 
low risk category; 1 = intermediate risk category; 2 = high risk category. In each plot the results for the 
following regression parameters are provided: b = regression coefficient, a = intercept (constant), p value 
for test for statistical significance of the regression coefficient. The relationship between each couple of 
scores can be summarized as: risk category based on score y = a + b(risk category based on score x), and 
result should be interpreted accounting for the categorical nature of the variables. The more the line 
resembles the 45° line (a=0 and b=1), the closer the co-classification is to the perfect coincidence between 
cardio-embolic and bleeding risk category. 
The fist two plots (a and b)at the top of the figure depict the relationship between cardio-embolic 
risk categories or bleeding risk categories as defined by different scores. For example patients at low 
CHADS2 score (“0”) belonged on average to a CHA2DS2–VASc category of “1.79”, i.e. some patients were 
classified at intermediate (“1”), some patients at high CHA2DS2–VASc risk (“2”); patients at intermediate 
CHADS2 score (1) belonged on average to a CHA2DS2–VASc category of “1.9” (=1.79+1*0.11), i.e. practically 
all the patients were reclassified as at high CHA2DS2–VASc risk (“2”); the flat line points out the fact the 
almost all the population was at high CHA2DS2–VASc score. Similarly, patients at low HEMORR2HAGES (0) 
risk belonged on average to a HAS-BLED category of 0.96 (≅1, i.e. almost all were at intermediate risk 
according to HASBLED); patients at intermediate HEMORR2HAGES risk (category “1”) belonged on average 
to a HAS-BLED category of “1.45” (=0.96+1*0.49) (i.e. about half of the patients were at intermediate and 
half at high risk according to HAS-BLED). 
The plots c, d, e and f, showing the relationship between cardio-embolic risk categories and 
bleeding risk categories using different combination of scores, can be similarly interpreted. Overall the 
regression equations point out that, independently of the couple of scores used (even if less evidently 
when CHA2DS2–VASc and HAS-BLED are compared), the patient cardio-embolic risk category was on 
average higher than the bleeding risk category. 
 
 Figure 2. CART analysis: risk scores as predictors of VKA prescription 
The figure shows the results of a CART analysis where all the scores were entered as independent variables 
and the prescription of VKAs (yes/no) was the outcome. In the figure: N = number of patients in each 
branch; F = number of failures (= patients prescribed with VKA) in each branch; RPR = Relative Prescription 
Ratio (where a RPR=1 represents a hypothetical point of indifference for VKA prescription) for each branch. 
The analyses retained the CHADS2 and the HEMORR2HAGES scores as the most significant predictors of 
VKAs prescription. In particular, the HEMORR2HAGES score was that best-splitting the population between 
those more and less likely to receive VKAs, with a score of 3 as that theoretically overturning the chance of 
being prescribed with VKAs. The value of CHADS2 score appeared to have a secondary effect: among 
patients less likely to receive VKAs because of their higher HEMORR2HAGES score, a high value of CHADS2 
score seemed to increase the chance of VKA prescription. 
 Figure 1. Relationship between risk categories according to cardio-embolic and bleeding risk scores, 
based on standard linear regressions 
 
Figure 2. CART analysis: risk scores as predictors of VKA prescription. 
 
 
N = number of patients in each branch; F = number of failures (= patients prescribed with VKA) in each 
branch; RPR = Relative Prescription Ratio 
 
N F RHR
HEMORR 2HAGES 
0 -2 159 32 .48
3-7 
CHADS2
3 -6 120 45 .90
0-2 264 149 1.36 
CART analysis - Split if (adjusted) P<.05.  Dependent variable: VKA prescription at admission
 
Indep. variables: CHADS2, CHA2DS2-VASc, HEMORR2HAGES, HAS-BLED* 
